Patents by Inventor Joel Moore
Joel Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170065586Abstract: The present patent application discloses at least the compounds according to Formula I or Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring B, JB, n, JD, J, o, X, RC and RA are as described herein.Type: ApplicationFiled: September 15, 2016Publication date: March 9, 2017Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Takashi NAKAI, Nicholas Robert PERL, Joel MOORE
-
Patent number: 9586937Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: July 21, 2016Date of Patent: March 7, 2017Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, James Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
-
Publication number: 20160375022Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: August 24, 2016Publication date: December 29, 2016Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, Rajesh R. IYENGAR, Ara MERMERIAN, G-Yoon Jamie IM, Thomas Wai-Ho LEE, Colleen HUDSON, Glen Robert RENNIE, James JIA, Paul Allan RENHOWE, Timothy Claude BARDEN, Xiang Y. YU, James Edward SHEPPECK, Karthik IYER, Joon JUNG, George Todd MILNE, Kimberly Kafadar LONG, Mark G. CURRIE
-
Publication number: 20160347738Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: July 21, 2016Publication date: December 1, 2016Inventors: Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, Rajesh R. IYENGAR, Ara MERMERIAN, G-Yoon Jamie IM, Thomas Wai-Ho LEE, Colleen HUDSON, Glen Robert RENNIE, James JIA, Paul Allan RENHOWE, Timothy Claude BARDEN, Xiang Y. YU, James Edward SHEPPECK, Karthik IYER, Joon JUNG, George Todd MILNE, Kimberly Kafadar LONG, Mark G. CURRIE
-
Patent number: 9487508Abstract: The present patent application discloses at least the compounds according to Formula I or Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring B, JB, n, JD, J, o, X, RC and RA are as described herein.Type: GrantFiled: September 19, 2013Date of Patent: November 8, 2016Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventors: Takashi Nakai, Nicholas Robert Perl, Joel Moore
-
Patent number: 9481689Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: March 14, 2014Date of Patent: November 1, 2016Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, James Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
-
Publication number: 20160264554Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.Type: ApplicationFiled: October 17, 2014Publication date: September 15, 2016Inventors: Nathanael Gray, Tinghu Zhang, Stephane Ciblat, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, M. Arshad Siddiqui, Anzhelika Kabro, Tom Miller, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley
-
Publication number: 20160264552Abstract: The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: October 17, 2014Publication date: September 15, 2016Inventors: Stephane Ciblat, Patrick Deroy, Melissa Leblanc, Jason J. Marineau, Joel Moore, Stephanie Roy, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Anzhelika Kabro, Serge Leger, Tom Miller, Darby Schmidt, Michael Bradley
-
Publication number: 20160264551Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, in duce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: October 17, 2014Publication date: September 15, 2016Applicants: SYROS PHARMACEUTICALS, INC., DANA-FARBER CANCER INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Tom Miller, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley
-
Publication number: 20160175307Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: February 26, 2016Publication date: June 23, 2016Applicant: Ironwood Pharmaceuticals, Inc.Inventors: G-Yoon Jamie IM, Rajesh IYENGAR, Joel MOORE, Angelika FRETZEN
-
Patent number: 9309235Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: September 18, 2013Date of Patent: April 12, 2016Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventors: G-Yoon Jamie Im, Rajesh Iyengar, Joel Moore, Angelika Fretzen
-
Publication number: 20160031903Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, Rajesh R. IYENGAR, Ara MERMERIAN, G-Yoon Jamie IM, Thomas Wai-Ho LEE, Colleen HUDSON, Glen Robert RENNIE, James JIA, Paul Allan RENHOWE, Timothy Claude BARDEN, Xiang Y. YU, James Edward SHEPPECK, Karthik IYER, Joon JUNG, George Todd MILNE, Kimberly Kafadar LONG
-
Publication number: 20150342954Abstract: Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: August 12, 2015Publication date: December 3, 2015Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Charles KIM, Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, G-Yoon Jamie IM, Timothy Claude BARDEN, Rajesh R. IYENGAR, Daniel P. ZIMMER, Angelika FRETZEN, Paul Allan RENHOWE
-
Publication number: 20150274712Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: September 18, 2013Publication date: October 1, 2015Inventors: G-Yoon Jamie IM, Rajesh IYENGAR, Joel MOORE, Angelika FRETZEN
-
Patent number: 9139564Abstract: Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: December 26, 2012Date of Patent: September 22, 2015Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventors: Charles Kim, Takashi Nakai, Joel Moore, Nicholas Robert Perl, G-yoon Jamie Im, Timothy Claude Barden, Rajesh R. Iyengar, Daniel P. Zimmer, Angelika Fretzen, Paul Allan Renhowe
-
Publication number: 20150250795Abstract: Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: April 28, 2015Publication date: September 10, 2015Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Charles KIM, Takashi NAKAI, Thomas Wai-Ho LEE, Joel MOORE, Nicholas Robert PERL, Jason ROHDE
-
Publication number: 20150232461Abstract: The present patent application discloses at least the compounds according to Formula I or Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring B, JB, n, JD, J, o, X, RC and RA are as described herein.Type: ApplicationFiled: September 19, 2013Publication date: August 20, 2015Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Taakshi NAKAI, Nicholas Robert PERL, Joel MOORE
-
Patent number: 9061030Abstract: Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: November 2, 2011Date of Patent: June 23, 2015Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventors: Charles Kim, Takashi Nakai, Thomas Wai-Ho Lee, Joel Moore, Nicholas Robert Perl, Jason Rohde
-
Publication number: 20150018353Abstract: Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: December 26, 2012Publication date: January 15, 2015Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Charles Kim, Takashi Nakai, Joel Moore, Nicholas Robert Perl, G-yoon Jamie Im, Timothy Claude Barden, Rajesh R. Iyengar, Daniel P. Zimmer, Angelika Fretzen, Paul Allan Renhowe
-
Publication number: 20140323448Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: April 29, 2014Publication date: October 30, 2014Applicant: Ironwood Pharmaceuticals Inc.Inventors: Charles KIM, Takashi NAKAI, Thomas Wai-Ho LEE, Joel MOORE, Nicholas Robert PERL, Jason ROHDE, Rajesh R. IYENGAR, Ara MERMERIAN, Angelika FRETZEN